Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies
Summary
Funding Led by Tramway Venture Partners Includes Key Appointments to the Board and Accelerates the Development of High-Dose Lung Delivery Solutions.ALBUQUERQUE, N.M., August 6, 2024-- Nob Hill Therapeutics (NHT), an early-stage pulmonary medical device and therapeutics company, today announced the first close of a $3 million Series A financing round. Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that cannot be effectively treated today. The funds will support continued development of Nob Hills high-dose respiratory technology and therapeutics, including pre-IND studies. Noel Greenberger, CEO of NHT, added, "We continue to advance our goal of being the leading provider of high-dose lung delivery solutions. NHTs patented Dry Powder Nebulizer platform has several technological innovations that enable it to generate highly efficient drug aerosols and deliver them effectively to the lower respiratory tract, independent of the patients lung capacity.